Section Arrow
IMMP.NASDAQ
- Immutep Limited
(Financial Status)
Quotes are at least 15-min delayed:2026/07/16 17:47 EDT
After Hours
Last
 0.4301
-0.0055 (-1.26%)
Bid
0.4209
Ask
0.4466
High 0.4466 
Low 0.4301 
Volume 310 
Regular Hours (Closed)
Last
 0.4356
-0.0011 (-0.25%)
Day High 
0.4466 
Prev. Close
0.4367 
1-M High
0.459 
Volume 
200.73K 
Bid
0.4209
Ask
0.4466
Day Low
0.435 
Open
0.4367 
1-M Low
0.3559 
Market Cap 
64.36M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.43 
20-SMA 0.41 
50-SMA 0.42 
52-W High 3.5299 
52-W Low 0.2928 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.57/-0.37
Enterprise Value
64.67M
Balance Sheet
Book Value Per Share
0.46
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc0.1477+0.0332+29.00%-- 
After Hours 0.1455 -0.0022 -1.49%
ATAIAtaiBeckley Inc7.15+1.79+33.40%-- 
After Hours 7.08 -0.07 -0.98%
KAPAKairos Pharma Ltd.0.3399+0.0219+6.89%-- 
After Hours 0.347 +0.0071 +2.09%
RXRXRecursion Pharmaceuticals3.02-0.29-8.76%-- 
After Hours 3.04 +0.02 +0.66%
IOVAIovance Biotherapeutics4.66-0.08-1.69%-- 
After Hours 4.6531 -0.0069 -0.15%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.